Kelly Martin has been named permanent CEO of Novan (NASDAQ: [[ticker:NOVN]]). The Morrisville, NC-based drug developer appointed Martin interim CEO last June, part of a corporate shakeup in which the company laid off 20 percent of its staff and shifted founding CEO Nathan Stasko to chief scientific officer. Those moves followed the failure of SB204, a topical gel developed to treat acne, in one of two Phase 3 studies in early 2017.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
